期刊文献+

经典型骨肉瘤中Hes1蛋白的表达及其临床意义 被引量:1

Expression of Hes1 protein in conventional osteosarcoma and its clinical significance
下载PDF
导出
摘要 目的研究发状分裂相关增强子1(hairy and enhancer of split 1,Hes1)蛋白在经典型骨肉瘤中的表达及其与临床特征和预后的关系。方法收集本院2007年4月至2016年10月初诊初治并明确诊断的经典型骨肉瘤患者标本56例,运用免疫组织化学检测Hes1蛋白的表达,分析其表达与临床病理特征及术后转归的关系。对患者总生存和无进展生存情况进行随访,随访至术后5年,采用Kaplan-Meier法和log-rank检验进行生存分析。结果56例患者中,Hes1高表达22例(39.3%),低表达34例(60.7%)。与Hes1低表达患者比较,Hes1高表达患者的肿瘤直径更大(P=0.018),术后复发率及转移率均更高(均P<0.05)。Hes1低表达和高表达患者5年内平均总生存期为52.7个月和38.4个月(P=0.001),5年内平均无进展生存期为48.3个月和22.6个月(P<0.01)。Cox多因素回归分析提示,Hes1表达水平是患者总生存和无进展生存的预后独立风险因素(均P<0.01)。结论经典型骨肉瘤中Hes1蛋白的高表达与术后复发、转移及生存时间缩短相关。 Objective To investigate the expression of hairy and enhancer of split 1(Hes1)protein in conventional osteosarcoma,and to explore the relationship between the expression and the clinical features and prognosis of conventional osteosarcoma.Methods From April 2007 to October 2016,56 patients with conventional osteosarcoma who were initially diagnosed and treated in our hospital were collected.Immunohistochemistry was used to detect the expression of Hes1 protein,and the relationship between the expression and the clinicopathological parameters of patients and their prognosis were analyzed.The overall survival and progression-free survival of the patients were followed up until 5 years after surgery,and the Kaplan-Meier method and log-rank test were used for survival analysis.Results Hes1 was highly expressed in 22 cases(39.3%),and lowly expressed in 34 cases(60.7%).Compared with patients with low expression of Hes1,patients with high expression of Hes1 had larger tumor diameters(P=0.018),higher tumor relapse and metastasis rates(both P<0.05).Within the 5-year follow-up,the mean overall survival time of patients with low and high Hes1 expression was 52.7 months and 38.4 months(P=0.001),and the mean progression-free survival time was 48.3 months and 22.6 months(P<0.01).Cox multivariate regression analysis showed that Hes1 expression was an independent risk factor of osteosarcoma prognosis for overall survival and progression-free survival(both P<0.01).Conclusions The high expression of Hes1 protein in conventional osteosarcoma is associated with tumor relapse,metastasis and shortened survival time.
作者 赖续文 罗锦霞 崔文志 刘姗姗 王蔚 闫广宁 Lai Xuwen;Luo Jinxia;Cui Wenzhi;Liu Shanshan;Wang Wei;Yan Guangning(Department of Pathology,General Hospital of Southern Theatre Command,People’s Liberation Army of China,Guangzhou 510010,China)
出处 《实用肿瘤杂志》 CAS 2022年第4期315-319,共5页 Journal of Practical Oncology
基金 国家自然科学基金青年科学基金项目(81802962)。
关键词 经典型骨肉瘤 发状分裂相关增强子1 复发 转移 预后 conventional osteosarcoma hairy and enhancer of split 1 relapse metastasis prognosis
  • 相关文献

参考文献4

二级参考文献32

  • 1Longhi A, Errani C, De Paolis M ,et al. Primary bone osleo- sarcoma in the pediatric age: state of the art [ J ]. Cancer Treat Rev,2006,32(6) :423.
  • 2Wittig JC, Bickels J, Priebat D, et al. Osteosarcoma : a mul- tidisciplinary approach to diagnosis and treatment [ J ]. Am Fam Physician ,2002,65(6) :1123.
  • 3Berman SD,Calo E, I,andman AS,et al. Metastatic osteo- sarcoma induced by inactivation of Rb and p53 in the osle- oblast lineage [ J ]. Proc Natl Acad Sci USA, 2008, 105 (33) :11851.
  • 4Link MP,Goorin AM, Miser AW,et al. The effect of adju- vant chemotherapy on relapse-free survival in patients with osteosareoma of the extremity[ J ]. N Engl J Med,1986,314 ( 25 ) : 1600.
  • 5Allenspach EJ, Maillard I, Aster JC,et al. Notch signaling in cancer[ J ]. Cancer Biol Ther,2002,1 (5) :466.
  • 6Weng AP,Ferrando AA,Lee W,et al. Activating mulations of NOTCH1 in human T cell acute lymphoblastie leukemia [ J ]. Science, 2004,306 ( 5694 ) : 269.
  • 7Bielack SS, Kempf-Bielack B, Delling G, e! al. Prognosticfactors in high-grade osteosarcoma of the extremities or trunk : an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [ J ]. J Clin Oncol, 2002,20 ( 3 ) : 776.
  • 8Carrie D,Bielack SS. Current strategies of chemotherapy in osteosarcoma [ J ]. Int Orthop ,2006,30 ( 6 ) :445.
  • 9Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metas- tasis and poor clinical outcome in inflammatory breast cancer [ J ]. Clin Cancer Res, 20 l 0,16 ( 1 ) :45.
  • 10Meyers PA,Schwartz CL, Krailo MD,et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy "im- proves overall survival:a report from the Childreng Oncolo- gy Group [ J ]. J Clin Oncol,2008,26 (4) :633.

共引文献15

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部